Burg Simpson is not currently pursuing new Zyprexa® cases.
Zyprexa® (olanzapine), a second-generation anti-psychotic drug manufactured by Eli Lilly which was approved to treat schizophrenia and bipolar mania, has been linked to serious side effects including diabetes, hyperglycemia and other blood sugar disorders.
In January of 2004, the FDA asked all manufacturers of atypical antipsychotic medications, including Eli Lilly, to add a Warning statement describing the increased risk of hyperglycemia and diabetes in patients taking these medications, including Zyprexa®.
Eli Lilly then issued a letter to doctors which included the warning statement describing this risk to patients taking Zyprexa, as well as a revised drug label with these warnings included in it.
In June 2005, Eli Lilly agreed to pay $690 million to settle approximately 8,000 lawsuits in the first round of the Zyprexa® litigation. The lawsuits alleged not only the manufacturer’s negligence in delivering more clear warnings about potentially severe side effects once issues were known, but also the promotion of drugs like Zyprexa® for uses not approved by the FDA, which had not yet been determined safe and effective.
Burg Simpson Attorneys at the Forefront of Zyprexa® Litigation
Michael S. Burg was appointed to the Plaintiffs’ Steering Committee for the Zyprexa® Multidistrict Litigation, and Seth A. Katz served as Chair of the Discovery Committee for the Zyprexa® Multidistrict Litigation.